FrancophonIA/ELRC3.0 huggingface dataset:
English: Gastroduodenal carcinomas, an increased incidence of background haemangiosarcomas, and/or gastric mucosal hyperplasia were observed at doses of ≥ 25 mg/kg/day following 1- or 6-months duration (≥ 7.3 times the AUC in patients administered the recommended daily dose RDD).
Croatian: Zabilježeni su gastroduodenalni karcinomi, povećana incidencija hemangiosarkoma i/ili hiperplazija želučane sluznice pri dozama od ≥ 25 mg/kg/dan nakon 1 ili 6 mjeseci primjene (što predstavlja ≥ 7,3 puta veći AUC nego u bolesnika koji su dobivali preporučenu dnevnu dozu).
English: The pivotal study in pancreatic NET was terminated prematurely at the recommendation of an independent drug monitoring committee and the primary endpoint was based upon investigator assessment, both of which may have affected the estimates of the treatment effect.
Croatian: Pivotalno ispitivanje neuroendokrinih tumora gušterače završeno je prije vremena po preporuci neovisnog odbora za praćenje lijekova te se primarna mjera ishoda temeljila na procjeni ispitivača.
English: Hypertension was reported in approximately 33.9% of patients receiving sunitinib for treatment-naïve MRCC compared to 3.6% of patients receiving IFN-.
Croatian: Hipertenzija je prijavljena u približno 33,9% bolesnika koji su za liječenje prethodno neliječenog MRCC-a primali sunitinib u odnosu na 3,6% bolesnika koji su primali IFN-α.
English: Reversal of the effects of TMA has been observed after treatment discontinuation (see section 4.8).
Croatian: Povlačenje učinaka TMA primijećeno je nakon prekida liječenja (vidjeti dio 4.8).
English: Sutent 12.5 mg hard capsules Sutent 25 mg hard capsules Sutent 37.5 mg hard capsules Sutent 50 mg hard capsules
Croatian: Sutent 12,5 mg tvrde kapsule Sutent 25 mg tvrde kapsule Sutent 37,5 mg tvrde kapsule Sutent 50 mg tvrde kapsule
English: Rare: may affect up to 1 in 1,000 people
Croatian: Rijetke nuspojave: mogu se javiti u manje od 1 na 1000 osoba
English: If indicated, elimination of unabsorbed active substance may be achieved by emesis or gastric lavage.
Croatian: Ako za to postoji indikacija, eliminacija neapsorbiranog lijeka može se postići izazivanjem povraćanja ili ispiranjem želuca.
English: Tell your doctor if you develop any of the following signs and symptoms of liver problems during Sutent treatment: itching, yellow eyes or skin, dark urine, and pain or discomfort in the right upper stomach area.
Croatian: Obavijestite liječnika ako se tijekom liječenja lijekom Sutent razvije bilo koji od sljedećih znakova i simptoma: svrbež, žutilo bjeloočnica ili kože, tamna mokraća te bol ili neugoda u gornjem desnom dijelu trbuha.
English: Abbreviations: CI=confidence interval; ITT=intent-to-treat; NA=not applicable; ORR=objective response rate; OS=overall survival; PFS=progression-free survival; TTP=time-to-tumour progression.
Croatian: Kratice: CI = interval pouzdanosti; ITT = populacija s namjerom liječenja; NA = nije primjenjivo; ORR = stopa objektivnog odgovora; OS = ukupno preživljenje; PFS = preživljenje bez progresije bolesti; TTP = vrijeme do progresije tumora.
English: Selection of an alternative concomitant medicinal product with no or minimal potential to induce or inhibit CYP3A4 should be considered.
Croatian: Treba razmotriti odabir drugog lijeka za istodobnu primjenu, a koji nema ili ima neznatan potencijal za indukciju ili inhibiciju CYP3A4.
English: The most frequent adverse drug reactions were diarrhoea, nausea, WBC count decreased, neutropenia, and headache in 3 (50.0%) patients each, primarily Grade 1 or 2 in severity.
Croatian: Najčešće nuspojave prvenstveno 1. ili 2. stupnja težine bile su proljev, mučnina, smanjenje broja leukocita, neutropenija i glavobolja te se svaka od njih pojavila u 3 (50,0 %) bolesnika.
English: • Fluid around the heart (pericardial effusion).
Croatian: • Tekućina oko srca (perikardijalni izljev).
English: Baseline urinalysis is recommended, and patients should be monitored for the development or worsening of proteinuria.
Croatian: Preporučuje se analiza mokraće prije početka liječenja kao i praćenje bolesnika u smislu pojave ili pogoršanja proteinurije.
English: The median OS was 114.6 weeks for the sunitinib arm (95% CI: 100.1, 142.9) and 94.9 weeks for the IFN-α arm (95% CI: 77.7, 117.0) with a hazard ratio of 0.821 (95% CI: 0.673, 1.001; p=0.0510 by unstratified log-rank).
Croatian: Medijan ukupnog preživljenja iznosio je 114,6 tjedana u skupini liječenoj sunitinibom (95% CI: 100,1; 142,9), a 94,9 tjedana skupini liječenoj IFN-α (95% CI: 77,7; 117,0), uz omjer hazarda od 0,821 (95% CI: 0,673; 1,001, p = 0,0510 po nestratificiranom log-rang testu).
English: If fistula formation occurs, sunitinib treatment should be interrupted.
Croatian: Dođe li do formiranja fistule, treba privremeno prekinuti liječenje sunitinibom.
English: Decreased absolute neutrophil counts of Grade 3 and 4 severities, respectively, were reported in 10% and 1.7% of patients on the Phase 3 GIST study, in 16% and 1.6% of patients on the Phase 3 MRCC study, and in 13% and 2.4% of patients on the Phase 3 pNET study.
Croatian: Smanjenje apsolutnog broja neutrofila 3. odnosno 4. stupnja težine, prijavljeno je u 10% i 1,7% bolesnika u ispitivanju GIST-a faze III, u 16% i 1,6% bolesnika u ispitivanju MRCC-a faze III te u 13% i 2,4% bolesnika u ispitivanju pNET-a faze III.
English: The investigator-assessed median PFS was 13.2 months, both in the overall population (95% CI: 10.9, 16.7) and in the treatment-naïve cohort (95% CI: 7.4, 16.8).
Croatian: Medijan PFS-a koji je ocijenio ispitivač iznosio je 13,2 mjeseca, i u sveukupnoj populaciji (95% CI: 10,9; 16,7) i u kohorti bolesnika koji prethodno nisu bili liječeni (95% CI: 7,4; 16,8).
English: Pancreatic neuroendocrine tumours (pNET)
Croatian: Neuroendokrini tumori gušterače (engl. pancreatic neuroendocrine tumours, pNET)
English: Risk factors associated with ATE, in addition to the underlying malignant disease and age  65 years, included hypertension, diabetes mellitus, and prior thromboembolic disease.
Croatian: Uz postojeću zloćudnu bolest i dob od ≥65 godina, faktori rizika povezani s arterijskim tromboembolijskim događajima uključivali su hipertenziju, šećernu bolest i prethodnu tromboembolijsku bolest.
English: There were no serious adverse events (SAEs) or Grade 5 adverse drug reactions reported in this study.
Croatian: U ovom ispitivanju nisu prijavljeni ozbiljni štetni događaji ili nuspojave 5. stupnja.
English: - If you have or have had liver problems.
Croatian: - ako imate ili ste ranije imali tegoba s jetrom.
English: Abbreviations: CI=confidence interval; N=number of patients; PFS=progression-free survival; pNET=pancreatic neuroendocrine tumours.
Croatian: Kratice: CI = interval pouzdanosti, N = broj bolesnika, PFS = preživljenje bez progresije, pNET = neuroendokrini tumori gušterače
English: Tell your doctor if you develop fever, fatigue, tiredness, bruising, bleeding, swelling, confusion, vision loss, and seizures.
Croatian: Obavijestite liječnika ako nastupe vrućica, umor, modrice, krvarenje, oticanje, smetenost, gubitak vida i napadaji.
English: Hyperthyroidism was reported in no sunitinib-treated patients and 1 (1.0%) patient receiving standard of care.
Croatian: Hipertireoza nije zabilježena ni u jednog bolesnika liječenog sunitinibom, ali je zabilježena u 1 (1,0%) bolesnika na standardnom liječenju.
English: Skin and tissue disorders
Croatian: Poremećaji kože i potkožnog tkiva
English: Events of tumour haemorrhage, sometimes associated with tumour necrosis, have been reported; some of these haemorrhagic events were fatal.
Croatian: Prijavljeni su slučajevi krvarenja tumora, ponekad udruženi s nekrozom tumorskog tkiva; neka od tih krvarenja završila su smrću.
English: QT interval prolongation may lead to an increased risk of ventricular arrhythmias including Torsade de pointes.
Croatian: Produljenje QT-intervala i torsade de pointes opaženi su u bolesnika izloženih sunitinibu.Produljenje QT-intervala može dovesti do povišenog rizika od ventrikularnih aritmija, uključujući torsade de pointes.
English: A supportive Phase 2, open-label, multi-centre study evaluated the efficacy and safety of single-agent sunitinib 50 mg daily on Schedule 4/2 in patients with unresectable pNET.
Croatian: U suportivnom, otvorenom, multicentričnom ispitivanju faze II procjenjivala se djelotvornost i sigurnost sunitiniba kao jedinog lijeka u dozi od 50 mg na dan prema shemi 4/2 u bolesnika s neoperabilnim pNET-om.
English: Severe hypertension was reported in 10% of pNET patients on sunitinib and 3% of patients on placebo.
Croatian: Teška hipertenzija prijavljena je u 10% bolesnika s pNET-om koji su primali sunitinib i u 3% bolesnika koji su primali placebo.
English: - Printing ink: shellac, propylene glycol, sodium hydroxide, povidone and titanium dioxide
Croatian: - Tinta za označavanje: šelak, propilenglikol, natrijev hidroksid, povidon i titanijev dioksid
English: Limited information is available on the continued use of sunitinib in patients with fistulae (see section 4.8).
Croatian: Ograničeni su podaci o nastavku primjene sunitiniba u bolesnika s fistulama (vidjeti dio 4.8).
English: • Hot flushes.
Croatian: • Navale vrućine.
English: The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.
Croatian: Primarni metabolit u biokemijskim i staničnim testovima pokazuje sličnu potentnost kao i sunitinib.
English: The most serious adverse reactions associated with sunitinib, some fatal, are renal failure, heart failure, pulmonary embolism, gastrointestinal perforation, and haemorrhages (e.g., respiratory tract, gastrointestinal, tumour, urinary tract, and brain haemorrhages).
Croatian: Najozbiljnije nuspojave povezane sa sunitinibom, od kojih su neke fatalne, su zatajenje bubrega, zatajenje srca, plućna embolija, gastrointestinalna perforacija i krvarenja (npr. krvarenja u dišnom sustavu, probavnom sustavu, tumorska krvarenja te krvarenja u urinarnom traktu i krvarenje u mozgu).
English: A phase 2 open-label study was conducted in 29 patients comprised of 27 paediatric patients (aged 3 years to 16 years) and 2 young adult patients (aged 18 years to 19 years) with recurrent/progressive/refractory high grade glioma (HGG) or ependymoma.
Croatian: Otvoreno ispitivanje faze 2 provedeno je u 29 bolesnika te je obuhvaćalo 27 pedijatrijskih bolesnika (u dobi od 3 do 16 godina) i 2 mlađa odrasla bolesnika (u dobi od 18 do 19 godina) s rekurentnim/progresivnim/refraktornim gliomom visokog gradusa ili ependimomom.
English: Tell your doctor if you feel very tired, are short of breath, or have swollen feet and ankles.
Croatian: Obavijestite liječnika ako osjećate izrazit umor, nedostaje Vam daha ili Vam otiču stopala i zglobovi.
English: Therapy with Sutent should be initiated by a physician experienced in the administration of anticancer agents.
Croatian: Liječenje lijekom Sutent mora započeti liječnik s iskustvom u primjeni antineoplastičnih lijekova.
English: Sunitinib was not clastogenic in rat bone marrow in vivo.
Croatian: Sunitinib se nije pokazao klastogenim u koštanoj srži štakora in vivo.
English: Changes in sunitinib PK parameters were of no clinical significance and did not indicate any drug-drug interactions; however, considering the relatively low number of subjects (i.e. N=7+4) and the moderate-large interpatient variability in the pharmacokinetic parameters, caution needs to be taken when interpreting the PK drug-drug interaction findings from this study.
Croatian: Međutim, s obzirom na relativno mali broj ispitanika (tj. N = 7 + 4) i umjerenu do veliku varijabilnost među bolesnicima u farmakokinetičkim parametrima, potrebno je oprezno interpretirati rezultate FK interakcije između lijekova dobivene u ovom ispitivanju.
English: Cases of fistula formation, sometimes associated with tumour necrosis and regression, in some cases with fatal outcomes, have been reported (see section 4.4).
Croatian: Prijavljeni su slučajevi stvaranja fistule, ponekad povezani s nekrozom i regresijom tumora, u nekim slučajevima sa smrtnim ishodom (vidjeti dio 4.4).
English: Haemorrhagic events, some of which were fatal, reported in clinical studies with sunitinib and during postmarketing surveillance have included gastrointestinal, respiratory, urinary tract, and brain haemorrhages (see section 4.8).
Croatian: Hemoragični događaji prijavljeni tijekom kliničkih ispitivanja sunitiniba i za vrijeme praćenja nakon stavljanja lijeka u promet, od kojih su neki imali smrtni ishod, obuhvaćali su krvarenja u probavnom traktu, dišnom sustavu, mokraćnom sustavu i mozgu (vidjeti dio 4.8).
English: A 6-month, oral gavage carcinogenicity study (0, 8, 25, 75 [reduced to 50] mg/kg/day), with daily dosing was conducted in rasH2 transgenic mice.
Croatian: Provedeno je šestmjesečno istraživanje kancerogenosti na rasH2 transgeničnim miševima, uz dnevnu primjenu lijeka (0, 8, 25 ili 75 [sniženo na 50] mg/kg na dan) prisilnim hranjenjem.
English: Of patients receiving sunitinib for cytokine-refractory MRCC, 26% experienced bleeding.
Croatian: U 26% bolesnika koji su dobivali sunitinib za liječenje MRCC-a refraktornog na citokine nastupilo je krvarenje.
English: Sutent 12.5 mg hard capsules Sutent 25 mg hard capsules Sutent 37.5 mg hard capsules Sutent 50 mg hard capsules sunitinib
Croatian: Sutent 12,5 mg tvrde kapsule Sutent 25 mg tvrde kapsule Sutent 37,5 mg tvrde kapsule Sutent 50 mg tvrde kapsule sunitinib
English: Median OS in the ITT population was 72.7 weeks and 64.9 weeks (HR: 0.876; 95% CI: 0.679, 1.129; p=0.306), in the sunitinib and placebo arms, respectively.
Croatian: Medijan OS-a u ITT populaciji iznosio je 72,7 tjedana u skupini liječenoj sunitinibom, odnosno 64,9 tjedana u placebo skupini (HR: 0,876; 95% CI: 0,679; 1,129; p = 0,306).
English: In the other study hypothyroidism was reported in a total of 31 (13%) patients on sunitinib and 2 (0.8%) patients on capecitabine.
Croatian: U drugom ispitivanju hipotireoza je zabilježena u ukupno 31 (13%) bolesnika liječenog sunitinibom i 2 (0,8%) bolesnika na terapiji kapecitabinom.
English: In the presence of clinical manifestations of CHF, discontinuation of sunitinib is recommended.
Croatian: U slučaju kliničke manifestacije kongestivnog zatajenja srca preporučuje se prekinuti primjenu sunitiniba.
English: Patients should be advised that they may experience dizziness during treatment with sunitinib.
Croatian: Bolesnike treba upozoriti da tijekom liječenja sunitinibom mogu osjetiti omaglicu.
English: • Excessive reaction to an allergen including hay fever, skin rash, itchy skin, hives, swelling of body parts, and trouble breathing.
Croatian: • Burna reakcija na alergen uključujući peludnu groznicu, kožni osip, svrbež kože, koprivnjaču,
English: Excretion is primarily via faeces (61%), with renal elimination of unchanged active substance and metabolites accounting for 16% of the administered dose.
Croatian: Sunitinib se primarno izlučuje u fecesu (61%), dok se 16% primijenjene doze eliminira putem bubrega u obliku nepromijenjene djelatne tvari i metabolita.
English: Risk factors associated with renal impairment/failure in patients receiving sunitinib included, in addition to underlying RCC, older age, diabetes mellitus, underlying renal impairment, cardiac failure, hypertension, sepsis, dehydration/hypovolaemia, and rhabdomyolysis.
Croatian: Osim postojećeg RCC-a, faktori rizika povezani s oštećenjem/zatajenjem bubrega u bolesnika liječenih sunitinibom uključivali su stariju dob, šećernu bolest, postojeće oštećenje bubrega, zatajenje srca, hipertenziju, sepsu, dehidraciju/hipovolemiju i rabdomiolizu.
English: In patients who have previously received or are receiving intravenous bisphosphonates, invasive dental procedures should be avoided if possible (see section 4.8).
Croatian: Ako je moguće, treba izbjegavati invazivne stomatološke postupke u bolesnika koji su prethodno primali ili primaju intravenske bisfosfonate (vidjeti dio 4.8).
English: For GIST and MRCC, the recommended dose of Sutent is 50 mg taken orally once daily, for 4 consecutive weeks, followed by a 2-week rest period (Schedule 4/2) to comprise a complete cycle of 6 weeks.
Croatian: Za liječenje GIST-a i MRCC-a preporučena doza lijeka Sutent je 50 mg, a uzima se peroralno jedanput na dan tijekom 4 uzastopna tjedna, nakon čega slijedi dvotjedni period odmora (shema 4/2), tako da ukupan ciklus traje 6 tjedana.
English: A pivotal Phase 3, multi-centre, international, randomised, double-blind, placebo-controlled study of single-agent sunitinib was conducted in patients with unresectable pNET.
Croatian: Provedeno je pivotalno, multicentrično, međunarodno, randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje faze III sunitiniba kao jedinog lijeka u bolesnika s neoperabilnim pNET-om.
English: Hypertension was reported in 26.5% of patients receiving sunitinib in a Phase 3 pNET study, compared to 4.9% of patients receiving placebo.
Croatian: Hipertenzija je prijavljena u 26,5% bolesnika liječenih sunitinibom u odnosu na 4,9% bolesnika koji su primali placebo u ispitivanju pNET-a faze III.
English: In the same study, 4 out of 6 patients (66.7%) experienced Grade 3-4 treatment-related adverse events (Grade 3 hypophosphataemia, neutropenia, and thrombocytopenia in 1 patient each and a Grade 4 neutropenia in 1 patient).
Croatian: U istom su se ispitivanju pojavili štetni događaji 3.-4. stupnja povezani s liječenjem u 4 od 6 bolesnika (66,7 %) (hipofosfatemija, neutropenija i trombocitopenija 3. stupnja prijavljene su svaka u po 1 bolesnika, dok je neutropenija 4. stupnja prijavljena u 1 bolesnika).
English: v Skin reaction and skin disorder.
Croatian: Reakcija kože i poremećaj kože w
English: A Phase 2 open-label study was conducted in 29 patients comprised of 27 paediatric patients (aged 3 years to 16 years) and 2 young adult patients (aged 18 years to 19 years) with HGG or ependymoma.
Croatian: Otvoreno ispitivanje faze 2 provedeno je u 29 bolesnika te je obuhvaćalo 27 pedijatrijskih bolesnika (u dobi od 3 do 16 godina) i 2 mlađa odrasla bolesnika (u dobi od 18 do 19 godina) s gliomom visokog gradusa ili ependimomom.
English: Cardiovascular events, including heart failure, cardiomyopathy, left ventricular ejection fraction decline to below the lower limit of normal, myocarditis, myocardial ischaemia and myocardial infarction, some of which were fatal, have been reported in patients treated with sunitinib.
Croatian: U bolesnika liječenih sunitinibom prijavljeni su kardiovaskularni događaji, uključujući zatajenje srca, kardiomiopatiju,smanjenje istisne frakcije lijeve klijetke ispod donje granice normalnih vrijednosti, miokarditis, ishemiju miokarda i infarkt miokarda, od kojih su neki imali smrtni ishod.
English: Upon disease progression, patients were unblinded and placebo patients were offered access to open-label sunitinib in a separate extension study.
Croatian: Po progresiji bolesti otkrivena je slijepa šifra terapije te je bolesnicima koji su primali placebo ponuđeno otvoreno liječenje sunitinibom u zasebnom produljenju ispitivanja.
English: This event is generally reversible after sunitinib discontinuation.
Croatian: Ona se u pravilu povlači nakon prestanka uzimanja sunitiniba.
English: Severe hypertension was reported in 12% of treatment-naïve patients on sunitinib and < 1% of patients on IFN-.
Croatian: Teška hipertenzija prijavljena je u 12% prethodno neliječenih bolesnika koji su primali sunitinib i u <1% bolesnika koji su primali IFN-α.
English: Core radiology assessment was discontinued after the primary endpoint had been met. At the final analysis, the ORR as determined by the investigator's assessment was 46% (95% CI: 41%, 51%) for the sunitinib arm and 12.0% (95% CI: 9%, 16%) for the IFN-α arm (p<0.001).
Croatian: U završnoj je analizi ORR prema procjeni ispitivača iznosio 46% (95% CI: 41%, 51%) u skupini liječenoj sunitinibom te 12,0% (95% CI: 9%; 16%) u skupini koja je primala IFN-α (p < 0,001).
English: • Mouth pain/irritation, mouth sores/inflammation/dryness, taste disturbances, upset stomach,
Croatian: • Bol/iritacija u ustima, ranice/upala/suhoća u ustima, poremećaji okusa, želučane tegobe,
English: Combination with CYP3A4 inhibitors should therefore be avoided, or the selection of an alternate concomitant medicinal product with no or minimal potential to inhibit CYP3A4 should be considered.
Croatian: Stoga treba izbjegavati kombiniranu primjenu s inhibitorima CYP3A4, odnosno razmotriti primjenu nekog drugog lijeka koji minimalno ili uopće ne inhibira CYP3A4.
English: Tell your doctor if you have severe abdominal pain, fever, nausea, vomiting, blood in your stool, or changes in bowel habits.
Croatian: Obavijestite liječnika ako nastupi jaka bol u trbuhu, vrućica, mučnina, povraćanje, krv u stolici ili promjene uobičajenog ritma pražnjenja crijeva.
English: Cases of necrotising fasciitis, including of the perineum, sometimes fatal, have been reported (see also section 4.4).
Croatian: Prijavljeni su slučajevi nekrotizirajućeg fasciitisa, uključujući i perineuma, ponekad sa smrtnim ishodom (vidjeti i dio 4.4).
English: Combination with CYP3A4 inducers should therefore be avoided, or selection of an alternate concomitant medicinal product, with no or minimal potential to induce CYP3A4 should be considered.
Croatian: Stoga treba izbjegavati kombiniranu primjenu s induktorima CYP3A4, odnosno razmotriti primjenu nekog drugog lijeka koji minimalno ili uopće ne inducira CYP3A4.
English: A Phase 1 dose-escalation study of oral sunitinib was conducted in 35 patients comprised of 30 paediatric patients (aged 3 years to 17 years) and 5 young adult patients (aged 18 to 21 years), with refractory solid tumours, the majority of whom had a primary diagnosis of brain tumour.
Croatian: Ispitivanje faze I kojim se ispitivalo povećanja doze oralnog sunitiniba provedeno je u 35 bolesnika te je obuhvaćalo 30 pedijatrijskih bolesnika (u dobi od 3 do 17 godina) i 5 mlađih odraslih bolesnika (u dobi od 18 do 21 godine) oboljelih od refraktornih solidnih tumora, od kojih je većina uključena s primarnom dijagnozom tumora na mozgu.
English: Progression-free survival [median, months (95% CI)] by derived tumour response assessment based upon application of RECIST to investigator tumour assessments
Croatian: Preživljenje bez progresije bolesti [medijan, mjeseci (95% CI)] prema procjeni reakcije tumora primjenom RECIST kriterija na mjerenja tumora koja su provodili ispitivači Preživljenje bez progresije bolesti [medijan, mjeseci (95% CI)] prema slijepoj neovisnoj centralnoj procjeni tumora
English: Gastrointestinal disorders
Croatian: Gastrointestinalni stromalni tumor
English: Sunitinib therapy should be discontinued in patients who develop necrotising fasciitis, and appropriate treatment should be promptly initiated.
Croatian: U bolesnika koji razviju nekrotizirajući fasciitis potrebno je prekinuti liječenje sunitinibom i odmah započeti odgovarajuću terapiju.
English: Co-administration of sunitinib with potent CYP3A4 inducers, such as rifampicin, should be avoided (see sections 4.4 and 4.5).
Croatian: Treba izbjegavati istodobnu primjenu sunitiniba sa snažnim induktorima CYP3A4, kakav je rifampicin (vidjeti dijelove 4.4 i 4.5).
English: Cases of pulmonary haemorrhage, some with a fatal outcome, have been observed in clinical trials and have been reported in postmarketing experience in patients treated with sunitinib for MRCC, GIST, and lung cancer.
Croatian: U kliničkim su ispitivanjima opaženi, a nakon stavljanja lijeka u promet prijavljeni slučajevi plućnog krvarenja u bolesnika koji su primali sunitinib za liječenje MRCC-a, GIST-a i karcinoma pluća.
English: Patients should be screened for hypertension and controlled as appropriate.
Croatian: U bolesnika treba napraviti probir na hipertenziju, koju treba primjereno kontrolirati.
English: Skin and subcutaneous tissue disorders
Croatian: Poremećaji kože i mekih tkiva
English: BLISTER - 12.5 MG CAPSULES
Croatian: BLISTER- 12,5 MG KAPSULE
English: Acquired hypothyroidism was noted in 6.2% of GIST patients on sunitinib versus 1% on placebo.
Croatian: Stečena hipotireoza zabilježena je u 6,2% bolesnika s GIST-om koji su dobivali sunitinib naspram 1% bolesnika koji su primali placebo.